Results 171 to 180 of about 2,201,777 (199)

Acquired resistance mechanisms to osimertinib: The constant battle

Cancer Treatment Reviews, 2023
Lung cancer is the leading cause of cancer-related mortality worldwide. Detectable driver mutations have now changed the course of lung cancer treatment with the emergence of targeted therapy as a novel strategy that widely improved lung cancer prognosis, especially in metastatic patients.
David Planchard, Hampig Raphael Kourie
exaly   +3 more sources

Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S

Journal of Chemotherapy, 2022
Chemotherapy or involvement in a clinical trial remain the standard treatment for patients with EGFR mutant non-small cell lung cancer who have disease progression while receiving Osimertinib. Rapid progression, also known as flare-phenomenon, has been described after discontinuation of tyrosine kinase inhibitors.
Juan Bautista Blaquier, Gonzalo Recondo
openaire   +2 more sources

Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis

Pharmacological Research, 2023
Favorable clinical evidence suggests that the next trend in new treatments for advanced non-small cell lung cancer (NSCLC) will be combination therapies. However, inevitable epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance greatly limits the clinical efficacy of patients carrying EGFR-activating mutants.
Zhaoxia Wang, Chenchen Wei
exaly   +3 more sources

Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer

Acta Biomaterialia, 2021
Osimertinib (OSI) is the first FDA-approved third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It can be used for treating non-small cell lung cancer (NSCLC) patients with activating EGFR mutation and for patients who are resistant to first-generation EGFR TKIs due to T790M resistance mutation.
Shi-Yong Sun, Wu Chen
exaly   +3 more sources

BDTX-1535 Goes after Osimertinib Resistance

Cancer Discovery, 2021
Abstract According to a preclinical report, the investigational tyrosine kinase inhibitor BDTX-1535 may mitigate resistance to osimertinib, the standard of care for EGFR-mutant non–small cell lung cancer. It could also potentially treat central nervous system metastases, having shown preclinical efficacy in glioblastoma.
openaire   +2 more sources

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Journal of Thoracic Oncology
Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification, and other pathways ...
Asato Hashinokuchi
exaly   +3 more sources

Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer

Lung Cancer, 2019
Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). However, there is no established strategy for treatment following acquired resistance to this agent.
Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Hisaaki Tanaka, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura   +9 more
openaire   +2 more sources

MET amplification (amp) as a resistance mechanism to osimertinib.

Journal of Clinical Oncology, 2017
9020 Background: Osimertinib (osi) is an EGFR T790M inhibitor. Mechanisms (mech) of acquired resistance (AR) are under study. We report a cohort of osi-AR pts with extensive pre/post-osi tissue and plasma. Methods: We analyzed 23 pts with AR to osi.
Zofia Piotrowska, Kenneth Stephen Thress, Meghan Mooradian, Rebecca Suk Heist, Christopher G. Azzoli, Jennifer S. Temel, Coleen Rizzo, Rebecca J Nagy, Richard B. Lanman, Scott N. Gettinger, Tracey L. Evans, Aaron N. Hata, Alice Tsang Shaw, Lecia V. Sequist   +13 more
openaire   +1 more source

Two Driver Mutations Exist in Osimertinib-Resistant Patient Tumors

Cancer Discovery, 2022
Abstract Single cells demonstrate additional driver alterations along with initial EGFR mutations to drive resistance.
openaire   +2 more sources

Abstract 6804: Sanguinarine overcomes osimertinib resistance by inducing HMOX1-related ferroptosis in osimertinib resistant cells lines and tumors

Cancer Research
Abstract Epidermal Growth Factor Receptor (EGFR) gene, as a crucial oncogenic driver, plays a significant role in the occurrence and progression of non-small cell lung cancer (NSCLC). Osimertinib, as the latest generation of EGFR tyrosine kinase inhibitors (TKIs), has shown remarkable efficacy not only in patients with EGFR-sensitive ...
Rongzhong Xu, Liubing Lin
openaire   +1 more source